NVO240726C146000
- 0.01
- -0.05-83.33%
Novo-Nordisk A/S Newsroom
Novo Nordisk Secures UK Authorization for New Semaglutide Indication
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
Express News | Novo's Weight-Loss Drug Wegovy Receives UK Nod For Heart Disease
Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Novo Nordisk A/S - Share Repurchase Programme
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.
Up to 20% weight loss! Eli Lilly and Co's Theralogix (Tesofensine) approved in China, stronger effect than Sibutramine?
Is the competition intensifying?
Kamala Harris' Potential Impact on Health Care Stocks
Here Are Big Pharma's Leading Blockbuster Makers
Novo Nordisk A/S (NVO): The Most Profitable Stock of the Last 20 Years According to Analysts?
US stocks closed with all three major indices falling, with the S&P Nasdaq index seeing its largest weekly decline in three months. Technology stocks weakened, with Tesla down more than 4%, Nvidia down more than 2%, and CrowdStrike down more than 11%.
Investors accelerated their escape from technology stocks, with stocks and bonds in Europe and the United States being hit hard for two days. This week, the S&P 500 and Nasdaq fell by about 2% and 3.7%, respectively. The Nasdaq stopped its six-week continuous rise, while the Dow and small-cap indices rose by 0.7% and 1.7%, respectively. Chip stocks fell more than 3% on Friday and nearly 9% for the week. Nvidia also fell more than 8.7% for the past three months, making it the worst performer. The "seven sisters of technology" all fell for the week, and cybersecurity leader Crowdstrike, which triggered a global technology outage, fell 11% on Friday, the worst in nearly two years. The VIX panic index rose more than 32% for the week.
Novo Nordisk Options Trading: A Deep Dive Into Market Sentiment
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday; Set to End Week Down 4%
Eli Lilly and Co (LLY.US) weight-loss drug has been approved in China and will directly compete with Novo Nordisk (NVO.US).
Eli Lilly and Co (LLY.US) has obtained approval from the National Medical Products Administration (NMPA) for long-term weight management indications of Trulicity (dulaglutide) injection.
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
Eli Lilly Weight Loss Drug Approved in China
Express News | Novo Nordisk : BMO Raises Target Price to $170 From $163
Rivals Emerge to Ozempic and Zepbound -- but With a Lag -- Heard on the Street -- WSJ
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'